Movement Alert｜Regeneron Pharmaceuticals Intraday Rise 3.58% in Regular Trading, UBS Resumes Coverage With a Buy Rating

Market Focus10-15

On October 15, Regeneron Pharmaceuticals rose 3.58% in Regular Trading, trading at $798.725 per share, with turnover of $74.0854 million.

The clearest catalyst behind the move was an analyst action: UBS resumed coverage on Regeneron Pharmaceuticals with a Buy rating, arguing that the market is underestimating the long-term potential of blockbuster drug Dupixent, which helped lift sentiment toward the stock.

Additional company-specific fundamentals also offered support. Recent 84-week extension data from the phase 3 OPTIMA trial showed Pasatru maintained efficacy and a safety profile consistent with 56-week results in adults with fibrodysplasia ossificans progressiva. The drug was approved by the FDA in August for adult FOP, and the longer-term data reinforced confidence in its commercialization outlook.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment